Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C21H23N3O7 and a molecular weight of approximately 429 g/mol[1][2][3]. It belongs to the class of phenylpyrrolidines and features a tricyclic core structure with an acetamidophenyl substituent and an acetic acid moiety[1][2]. The compound is listed as experimental in DrugBank (DB07784), indicating it has been studied but not approved for clinical use or assigned to any marketed drug product[2]. There is no available information on its mechanism of action or therapeutic indication in public databases; it appears primarily in chemical and structural biology resources as a ligand for protein studies (notably PDBe Ligand Code FRA)[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [4-(4-acetylamino-phenyl)-3,5-dioxo-4-aza-tricyclo[5.2.2.0 2,6]undec-1-ylcarbamoyloxy]-acetic acid.